JP2016514956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514956A5 JP2016514956A5 JP2015561624A JP2015561624A JP2016514956A5 JP 2016514956 A5 JP2016514956 A5 JP 2016514956A5 JP 2015561624 A JP2015561624 A JP 2015561624A JP 2015561624 A JP2015561624 A JP 2015561624A JP 2016514956 A5 JP2016514956 A5 JP 2016514956A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cell
- pharmaceutical composition
- binds
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 239000013603 viral vector Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 241000702421 Dependoparvovirus Species 0.000 claims 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 241000713666 Lentivirus Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| US201361775524P | 2013-03-09 | 2013-03-09 | |
| US61/775,524 | 2013-03-09 | ||
| US201461928383P | 2014-01-16 | 2014-01-16 | |
| US61/928,383 | 2014-01-16 | ||
| US201461941729P | 2014-02-19 | 2014-02-19 | |
| US61/941,729 | 2014-02-19 | ||
| PCT/US2014/020919 WO2014138306A1 (en) | 2013-03-05 | 2014-03-05 | Engager cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018193647A Division JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514956A JP2016514956A (ja) | 2016-05-26 |
| JP2016514956A5 true JP2016514956A5 (OSRAM) | 2017-03-30 |
| JP6420776B2 JP6420776B2 (ja) | 2018-11-07 |
Family
ID=51491924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561624A Expired - Fee Related JP6420776B2 (ja) | 2013-03-05 | 2014-03-05 | 免疫療法のためのエンゲージャー細胞 |
| JP2018193647A Expired - Fee Related JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018193647A Expired - Fee Related JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160015749A1 (OSRAM) |
| EP (2) | EP3447072A3 (OSRAM) |
| JP (2) | JP6420776B2 (OSRAM) |
| AU (1) | AU2014225788B2 (OSRAM) |
| CA (1) | CA2904230A1 (OSRAM) |
| ES (1) | ES2681948T3 (OSRAM) |
| WO (1) | WO2014138306A1 (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4279513A3 (en) | 2010-11-30 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| EP2964241A1 (en) * | 2013-03-05 | 2016-01-13 | Baylor College Of Medicine | Oncolytic virus |
| CA2943943C (en) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| BR112016026299A2 (pt) * | 2014-05-13 | 2018-02-20 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão |
| AU2015338984A1 (en) * | 2014-10-31 | 2017-04-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified T cells |
| WO2016077638A1 (en) * | 2014-11-12 | 2016-05-19 | Memorial Sloan Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| US9963509B2 (en) | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| EP4424326A3 (en) * | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| EP4218777A3 (en) * | 2015-08-28 | 2023-08-23 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| SG10201912792YA (en) * | 2015-10-06 | 2020-02-27 | Univ Minnesota | Therapeutic compounds and methods |
| US20180280435A1 (en) * | 2015-10-09 | 2018-10-04 | Virginia Commonwealth University | T cell delivery of mda-7/il-24 to improve therapeutic eradication of cancer and generate protective antitumor immunity |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| LT3461261T (lt) | 2016-05-20 | 2025-08-25 | Harpoon Therapeutics, Inc. | Vienos grandinės kintamo fragmento cd3 surišantys baltymai |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| EP3472318B1 (en) * | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| EP3609914A4 (en) * | 2017-04-14 | 2021-04-14 | The General Hospital Corporation | CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST TUMOR MICRO ENVIRONMENT |
| EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| EP3647433B1 (en) | 2017-06-30 | 2023-04-12 | Osaka University | Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index |
| WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RECOMBINANT ANTIBODIES BINDING TO CD123 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| AU2019218989A1 (en) * | 2018-02-12 | 2020-08-27 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EA202092457A1 (ru) * | 2018-05-08 | 2021-08-10 | Ньюракл Сайенс Ко., Лтд. | Доставка антител к fam19a5 с помощью аденоассоциированного вируса (aav) |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| EP4285914A3 (en) * | 2018-10-25 | 2024-02-28 | Baylor College of Medicine | Oncolytic virotherapy and immunotherapy |
| MX2021006783A (es) * | 2018-12-10 | 2021-07-15 | Amgen Inc | Transposasa de piggybac mutada. |
| CN113412276A (zh) * | 2018-12-14 | 2021-09-17 | 蓝鸟生物公司 | 二聚化剂调节的免疫受体复合物 |
| EP3917548A4 (en) * | 2019-01-30 | 2023-05-03 | The Wistar Institute of Anatomy and Biology | DNA-ENCODED BISPECIFIC T-CELL ENGAGERS THAT TARGET CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPIES |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
| AU2020272074A1 (en) * | 2019-04-12 | 2021-11-25 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| CN111001016B (zh) * | 2019-12-20 | 2022-06-17 | 中国人民解放军陆军军医大学 | 一种vha抑制dr5在缺氧下精子生成减少的检测方法 |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP2023512071A (ja) * | 2020-01-30 | 2023-03-23 | ウモジャ バイオファーマ， インコーポレイテッド | 二特異性形質導入エンハンサー |
| EP3865513A1 (en) * | 2020-02-17 | 2021-08-18 | Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre | Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| CN113481165B (zh) * | 2020-07-16 | 2022-06-03 | 山东博安生物技术股份有限公司 | 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2023102119A1 (en) * | 2021-12-01 | 2023-06-08 | The Brigham And Women's Hospital, Inc. | Multispecific t cell engager polypeptides in combination with t cells for cancer therapy |
| KR102532260B1 (ko) * | 2022-07-07 | 2023-05-16 | 주식회사 유틸렉스 | 돌연변이 EGFR 및 EphA2를 동시 타겟하는 키메라 항원 수용체 |
| WO2024010119A1 (ko) * | 2022-07-07 | 2024-01-11 | 주식회사 유틸렉스 | 돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체 |
| WO2024040261A1 (en) * | 2022-08-19 | 2024-02-22 | The Children's Hospital Of Philadelphia | Gd2 bi-specific invariant natural killer t cell engagers and methods of use thereof |
| WO2025101551A1 (en) * | 2023-11-06 | 2025-05-15 | Regents Of The University Of Minnesota | Prostate-specific membrane antigen (psma)-binding peptides and method of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
| US7820166B2 (en) * | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| EP2292664B1 (en) * | 2003-10-16 | 2016-11-23 | Amgen Research (Munich) GmbH | Multispecific deimmunized CD3-binders |
| KR20080090441A (ko) * | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도 |
| US20080004413A1 (en) | 2006-06-30 | 2008-01-03 | Derek Schorzman | Carboxylic M2Dx-like siloxanyl monomers |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| JP2014500879A (ja) * | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP2872526B1 (en) * | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
-
2014
- 2014-03-05 US US14/773,327 patent/US20160015749A1/en not_active Abandoned
- 2014-03-05 JP JP2015561624A patent/JP6420776B2/ja not_active Expired - Fee Related
- 2014-03-05 ES ES14714473.7T patent/ES2681948T3/es active Active
- 2014-03-05 EP EP18171595.4A patent/EP3447072A3/en not_active Withdrawn
- 2014-03-05 EP EP14714473.7A patent/EP2964675B1/en not_active Revoked
- 2014-03-05 AU AU2014225788A patent/AU2014225788B2/en not_active Ceased
- 2014-03-05 WO PCT/US2014/020919 patent/WO2014138306A1/en not_active Ceased
- 2014-03-05 CA CA2904230A patent/CA2904230A1/en not_active Abandoned
-
2018
- 2018-08-22 US US16/109,615 patent/US20190117692A1/en not_active Abandoned
- 2018-10-12 JP JP2018193647A patent/JP6867347B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514956A5 (OSRAM) | ||
| JP2016512199A5 (OSRAM) | ||
| EA201791971A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
| JP2016104790A5 (OSRAM) | ||
| JP2020503891A5 (OSRAM) | ||
| JP2016185981A5 (OSRAM) | ||
| JP2018504907A5 (OSRAM) | ||
| JP2017176174A5 (OSRAM) | ||
| EA201891021A1 (ru) | Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| JP2018508509A5 (OSRAM) | ||
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| JP2017531427A5 (OSRAM) | ||
| EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
| MX420258B (es) | Proteínas de unión a nkg2d, cd16 y nectina 4. | |
| AU2018271872A1 (en) | A protein binding NKG2D, CD16 and ROR1 or ROR2 | |
| WO2017189964A3 (en) | Compositions for the treatment of disease | |
| JP2015535691A5 (OSRAM) | ||
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| EP4321171A3 (en) | Sirp alpha-antibody fusion proteins | |
| MX395257B (es) | Anticuerpos para cd40. | |
| JP2012136541A5 (OSRAM) | ||
| JP2016531927A5 (OSRAM) | ||
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| JP2017501695A5 (OSRAM) | ||
| JP2016116527A5 (OSRAM) |